Campbell & CO Investment Adviser LLC grew its position in ChemoCentryx Inc (NASDAQ:CCXI) by 3.6% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 8,559 shares of the biopharmaceutical company’s stock after buying an additional 299 shares during the quarter. Campbell & CO Investment Adviser LLC’s holdings in ChemoCentryx were worth $469,000 at the end of the most recent quarter.
Other hedge funds have also recently made changes to their positions in the company. Bank of America Corp DE increased its position in shares of ChemoCentryx by 8.6% in the second quarter. Bank of America Corp DE now owns 54,145 shares of the biopharmaceutical company’s stock valued at $3,115,000 after buying an additional 4,292 shares in the last quarter. BNP Paribas Arbitrage SA boosted its stake in shares of ChemoCentryx by 207.1% during the first quarter. BNP Paribas Arbitrage SA now owns 14,710 shares of the biopharmaceutical company’s stock valued at $591,000 after acquiring an additional 9,920 shares during the last quarter. Invesco Ltd. boosted its stake in shares of ChemoCentryx by 95.2% during the first quarter. Invesco Ltd. now owns 316,233 shares of the biopharmaceutical company’s stock valued at $12,706,000 after acquiring an additional 154,265 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of ChemoCentryx by 10.6% during the first quarter. Geode Capital Management LLC now owns 634,532 shares of the biopharmaceutical company’s stock valued at $25,495,000 after acquiring an additional 60,979 shares during the last quarter. Finally, AXA acquired a new stake in shares of ChemoCentryx during the first quarter valued at $1,141,000. Institutional investors and hedge funds own 76.36% of the company’s stock.
A number of research firms recently commented on CCXI. Raymond James increased their price objective on ChemoCentryx from $95.00 to $100.00 and gave the company a “strong-buy” rating in a research note on Tuesday, August 11th. JPMorgan Chase & Co. decreased their price objective on ChemoCentryx from $64.00 to $61.00 and set an “overweight” rating on the stock in a research note on Wednesday, July 29th. BidaskClub raised ChemoCentryx from a “hold” rating to a “buy” rating in a research note on Saturday, September 19th. ValuEngine raised ChemoCentryx from a “hold” rating to a “buy” rating in a research note on Thursday, October 1st. Finally, TheStreet raised ChemoCentryx from a “d” rating to a “c” rating in a research note on Thursday, August 20th. One equities research analyst has rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company’s stock. ChemoCentryx currently has a consensus rating of “Buy” and a consensus target price of $71.10.
ChemoCentryx (NASDAQ:CCXI) last released its quarterly earnings data on Monday, August 10th. The biopharmaceutical company reported $0.29 earnings per share for the quarter, beating the consensus estimate of ($0.34) by $0.63. The business had revenue of $49.44 million for the quarter, compared to analyst estimates of $8.31 million. ChemoCentryx had a negative return on equity of 19.57% and a negative net margin of 39.19%. On average, equities research analysts expect that ChemoCentryx Inc will post -0.69 EPS for the current fiscal year.
In other news, major shareholder (International) Ltd Vifor sold 133,074 shares of ChemoCentryx stock in a transaction dated Friday, July 24th. The stock was sold at an average price of $54.62, for a total value of $7,268,501.88. The transaction was disclosed in a document filed with the SEC, which is available through this link. Insiders sold a total of 472,049 shares of company stock worth $25,581,734 over the last ninety days. Corporate insiders own 9.30% of the company’s stock.
ChemoCentryx, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), which is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis; and Phase IIb clinical trial, the AURORA trial for the treatment of patients with moderate-to-severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy.
Featured Article: What Is Dividend Yield and How Do You Calculate It?
Receive News & Ratings for ChemoCentryx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx and related companies with MarketBeat.com's FREE daily email newsletter.